目的 探討參芪扶正注射液聯(lián)合曲普瑞林治療晚期前列腺癌的治療效果及安全性。方法 選取2015年3月—2016年3月在重慶市開州區(qū)人民醫(yī)院就診的晚期前列腺癌患者83例，隨機(jī)分為對(duì)照組（42例）和治療組（41例）。對(duì)照組皮下注射注射用醋酸曲普瑞林，3.75 mg/次，3周/次。治療組在對(duì)照組治療基礎(chǔ)上靜脈滴注參芪扶正注射液，250 mL/次，1次/d，3周1個(gè)療程。兩組均間歇1周進(jìn)行下一個(gè)療程，兩組連續(xù)治療6個(gè)療程。治療后，觀察兩組的臨床療效、局部控制率、總生存率。比較兩組治療前后血清前列腺特異性抗原（PSA）、血清睪酮（T）、KPS評(píng)分的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為71.43%、85.37%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組患者PSA、T水平均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；治療后，治療組PSA、T水平顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，對(duì)照組和治療組KPS評(píng)分改善率分別為35.13%、52.50%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，對(duì)照組和治療組的局部控制率分別為52.38%、82.93%，兩組的總生存率分別為80.95%、97.56%，兩組局部控制率、總生存率比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 參芪扶正注射液聯(lián)合曲普瑞林治療晚期前列腺癌具有較好的臨床療效，可降低PSA和T水平，降低不良反應(yīng)發(fā)生率，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the therapeutic effect and safety of Shenqi Fuzheng Injection combined with triptorelin in treatment of advanced prostate cancer. Methods Patients (83 cases) with advanced prostate cancer in Kaizhou District People's Hospital in Chongqing from March 2015 to March 2016 were randomly divided into control (42 cases) and treatment (41 cases) groups. Patients in the control group were sc administered with Triptorelin Acetate for injection, 3.75 mg/time, three weeks/time. Patients in the treatment group were iv administered with Shenqi Fuzheng injection, 250 mL/time, once daily, and 3 weeks were as 1 course of treatment. Patients in two groups were treated for 6 courses. After treatment, the clinical efficacy, local control rate, and total survival rate were evaluated, and the changes of PSA, T and KPS score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 71.43% and 85.37%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of PSA and T in two groups were decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of PSA and T in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the KPS score improvement rate in the control and treatment groups were 35.13% and 52.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, the local control rate in the control and treatment groups were 52.38% and 82.93%, respectively, total survival rates in two groups were 80.95% and 97.56%, and there was difference between two groups (P < 0.05). Conclusion Shenqi Fuzheng Injection combined with triptorelin has clinical curative effect in treatment of advanced prostate cancer, can reduce the levels of PSA and T, and can reduce the incidence of adverse reactions, which has a certain clinical application value.